Page last updated: 2024-11-05

3-nitroaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-nitroaniline: used as a sole source of nitrogen , carbon and energy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7423
CHEMBL ID14068
SCHEMBL ID1487
SCHEMBL ID12707526
MeSH IDM0355863

Synonyms (86)

Synonym
3-aminonitrobenzene
ci azoic diazo component 7
ai3-52474
einecs 202-729-1
hsdb 2570
m-nitraniline
ci 37030
nitroaniline, 3-
nsc 9574
ccris 2318
AC-907/25014117
fast orange r base
wln: zr cnw
1-amino-3-nitrobenzene
3-nitrophenylamine
99-09-2
nitranilin
benzenamine, 3-nitro-
aniline, m-nitro-
diazo fast orange r
devol orange r
m-nitroaminobenzene
azobase mna
nsc9574
m-aminonitrobenzene
orange base irga i
daito orange base r
3-nitroaniline
fast orange mm base
c.i. azoic diazo component 7
amarthol fast orange r base
3-nitrobenzenamine
nsc-9574
c.i. 37030
hiltonil fast orange r base
fast orange base r
m-nitroaniline
m-nitrophenylamine
naphtoelan orange r base
fast orange r salt
fast orange m base
inchi=1/c6h6n2o2/c7-5-2-1-3-6(4-5)8(9)10/h1-4h,7h
3-nitro-aniline
NCGC00091126-01
GHL.PD_MITSCHER_LEG0.915
3-nitroaniline, analytical standard
3-nitroaniline, 98%
smr000343223
MLS000517063
MLS002415745
CHEMBL14068
3-nitro-phenylamine
N0117
AKOS000119115
STL137655
NCGC00091126-02
HMS2666G03
dtxcid505725
NCGC00257940-01
cas-99-09-2
tox21_200386
dtxsid6025725 ,
(3-nitrophenyl)-amine
meta-nitroaniline
m-nitroaniline [un1661] [poison]
unii-cm50sm561t
cm50sm561t ,
FT-0616230
3-nitroaniline [hsdb]
m-nitroaniline [mi]
nitroaniline, m-
SCHEMBL1487
3-nitrobenzeneamine
un 1661 (salt/mix)
m-nitro-aniline
3-nitro aniline
m-nitro aniline
SCHEMBL12707526
W-100051
STR01954
mfcd00007782
3-nitroaniline, 99%
Q2668442
D97675
EN300-17396
Z56924547

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This study presents a concentration-time threshold model in m-dinitrobenzene (m-DNB)-induced neurotoxicity in F344 rats based on pharmacokinetic modeling and variable duration infusions with neuropathological end points."( Pharmacokinetic factors and concentration-time threshold in m-dinitrobenzene-induced neurotoxicity.
Lister, T; Nolan, CC; Purcell, WM; Ray, DE; Xu, J, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" However, when the same total dosage was infused over periods of either 12 or 24 h, or 2, 4, or 6 days, the theoretical blood concentrations were from 21."( Pharmacokinetic factors and concentration-time threshold in m-dinitrobenzene-induced neurotoxicity.
Lister, T; Nolan, CC; Purcell, WM; Ray, DE; Xu, J, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.23870.003245.467312,589.2998AID2517
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.16890.006038.004119,952.5996AID1159521; AID1159523
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency53.32120.003041.611522,387.1992AID1159552
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency3.16230.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency66.82420.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1145613Drug absorption in rat small intestine1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID288191Membrane retention in permeability experiment with artificial membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1145612Dissociation constant, pKa of the compound at pH 5.31977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID233323Activity expressed by taste potency (taste intensity relative to sucrose on a mole/mole basis)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--taste relationship of perillartine and nitro- and cyanoaniline derivatives.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (14.29)18.7374
1990's2 (9.52)18.2507
2000's6 (28.57)29.6817
2010's9 (42.86)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.62 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index79.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]